Lipid and lipoprotein measurements and the risk of ischemic vascular events: Framingham Study

Neurology

Volumn 84, Issue 5, 2015, Pages 472-479

  Pikula, Aleksandra ^a,b   Beiser, Alexa S ^a,b   Wang, Jing ^a   Himali, Jayandra J ^a   Kelly Hayes, Margaret ^a,b   Kase, Carlos S ^b   Yang, Qiong ^a,b   Seshadri, Sudha ^a,b   Wolf, Philip A ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EFFECT SIZE; FEMALE; FOLLOW UP; GENETIC RISK; GENOTYPE; HEART INFARCTION; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTOR; STROKE; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; BRAIN ISCHEMIA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; TRIGLYCERIDES;

EID: 84925946670     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001202     Document Type: Article

References (34)

1. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-381.
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97: 1837-1847.
3. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104: 1108-1113.
4. Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: The Northern Manhattan Stroke Study. JAMA 2001;285: 2729-2735.
5. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004;63:1868-1875.
6. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: A systematic review. Atherosclerosis 2008; 196:489-496.
7. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology 2007;68:556-562.
8. Zhang Y, Tuomilehto J, Jousilahti P, Wang Y, Antikainen R, Hu G. Total and high-density lipoprotein cholesterol and stroke risk. Stroke 2012;43:1768-1774.
9. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death: The Framingham Study. Arch Intern Med 1981;141: 1128-1131.
10. Willey JZ, Xu Q, Boden-Albala B, et al. Lipid profile components and risk of ischemic stroke: The Northern Manhattan Study (NOMAS). Arch Neurol 2009;66: 1400-1406.
11. Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2003;34:623-631.
12. Psaty BM, Anderson M, Kronmal RA, et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc 2004; 52:1639-1647.
13. Brewer HB Jr. Increasing HDL cholesterol levels. N Engl J Med 2004;350:1491-1494.
14. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008;300:2142-2152.
15. Kim SJ, Park YG, Kim JH, Han YK, Cho HK, Bang OY. Plasma fasting and nonfasting triglycerides and high-density lipoprotein cholesterol in atherosclerotic stroke: different profiles according to low-density lipoprotein cholesterol. Atherosclerosis 2012;223: 463-467.
16. Laloux P, Galanti L, Jamart J. Lipids in ischemic stroke subtypes. Acta Neurol Belg 2004;104:13-19.
17. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198-3204.
18. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: The Framingham Study. Am J Public Health Nations Health 1951;41:279-281.
19. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: The Framingham Offspring Study. Am J Epidemiol 1979;110:281-290.
20. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1-8.
21. Warnick GR, Benderson J, Albers JJ. Dextran sulfate- Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-1388.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
23. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease: The Framingham Study. Ann Epidemiol 1992;2:23-28.
24. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639.
25. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk profile from the Framingham Study. Stroke 1991;22:312-318.
26. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89: 2595-2600.
27. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010;303:1832-1840.
28. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009;41:56-65.
29. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
30. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
31. Berger JS, McGinn AP, Howard BV, et al. Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women. Stroke 2012;43:958-966.
32. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008;358:1240-1249.
33. da Luz PL, Cesena FH, Favarato D, Cerqueira ES. Comparison of serum lipid values in patients with coronary artery disease at, 50, 50 to 59, 60 to 69, and 70 years of age. Am J Cardiol 2005;96:1640-1643.
34. Cholesterol, diastolic blood pressure, and stroke: 13, 000 strokes in 450, 000 people in 45 prospective cohorts. Prospective Studies Collaboration. Lancet 1995;346:1647-1653.